ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results

We recently published 10 Stock Winners Shocking Wall Street. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers last week.

ImmunityBio skyrocketed by 137 percent week-on-week to hit a new record high after rallying for 11 consecutive days, thanks to a flurry of catalysts, including a whopping surge in its sales, its expansion to a new international market, and the promising results from the clinical trial of its treatment candidate for a rare blood cancer.

In a recent clinical study of its CD19 CAR-NK treatment, in combination with rituximab, ImmunityBio Inc. (NASDAQ:IBRX) said that the therapy successfully controlled disease in four patients enrolled in the program, two of whom demonstrated complete remission at 7 and 15 months despite not receiving additional treatments after the initial eight doses.

After only two cycles, ImmunityBio Inc. (NASDAQ:IBRX) said the tumors disappeared completely. It said that the durability of complete response after ending the treatment underscores the potential for long-term immune-mediated disease control without continuous therapy.

Meanwhile, ImmunityBio Inc. (NASDAQ:IBRX) recently announced a 700 percent jump in preliminary revenues from its treatment, Anktiva, having raked in $113 million for the full-year 2025 amid strong demand.

ImmunityBio Inc. (NASDAQ:IBRX) is set to expand Anktiva in Saudi Arabia after securing the approval of the Food and Drug Administration to sell and market the drug in the country.

While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.